Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus prednisone (AAP) in BCR is unknown. Objective: To co...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher
Format:	article
Langue:	EN
Publié:	Elsevier 2021
Sujets:	Abiraterone Androgen deprivation therapy Androgen Biochemical recurrence Degarelix Prostate cancer Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/7cb29db5a1d04ef391276d51f770d34a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Documents similaires